O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson's disease
about
Versatile Structures of α-SynucleinMemory and synaptic plasticity are impaired by dysregulated hippocampal O-GlcNAcylation.Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 miceComparison of strategies for non-perturbing labeling of α-synuclein to study amyloidogenesis.Chemical Methods for Encoding and Decoding of Posttranslational ModificationsA small-angle X-ray scattering study of alpha-synuclein from human red blood cellsLoss of O-GlcNAc glycosylation in forebrain excitatory neurons induces neurodegeneration.The Sulfur-Linked Analogue of O-GlcNAc (S-GlcNAc) Is an Enzymatically Stable and Reasonable Structural Surrogate for O-GlcNAc at the Peptide and Protein Levels.Proteomic studies associated with Parkinson's disease.O-GlcNAcylation and neurodegeneration.Protein O-GlcNAcylation: emerging mechanisms and functions.The emerging link between O-GlcNAcylation and neurological disorders.Two-Dimensional Crowding Uncovers a Hidden Conformation of α-SynucleinO-GlcNAc regulation of autophagy and α-synuclein homeostasis; implications for Parkinson's disease.O-GlcNAc modification inhibits the calpain-mediated cleavage of α-synuclein.O-GlcNAcylation of α-Synuclein at Serine 87 Reduces Aggregation without Affecting Membrane Binding.Development of IsoTaG, a Chemical Glycoproteomics Technique for Profiling Intact N- and O-Glycopeptides from Whole Cell Proteomes.Nutrient-driven O-GlcNAc in proteostasis and neurodegeneration.Chemical biology approaches for studying posttranslational modifications.Segmental Deuteration of α-Synuclein for Neutron Reflectometry on Tethered Bilayers.Peptide microarray analysis of the cross-talk between O-GlcNAcylation and tyrosine phosphorylation.The Role of Stress-Induced O-GlcNAc Protein Modification in the Regulation of Membrane Transport.Mapping and quantification of over 2,000 O-linked glycopeptides in activated human T cells with isotope-targeted glycoproteomics (IsoTaG).Strategies and Considerations for Improving Expression of "Difficult to Express" Proteins in CHO Cells.Emerging Disease-Modifying Strategies Targeting α-Synuclein for the Treatment of Parkinson Disease.Semi-synthesis of a tag-free O-GlcNAcylated tau protein by sequential chemoselective ligation.Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson’s Disease.O-GlcNAc cycling in the developing, adult and geriatric brain.Cross-Dysregulation of -GlcNAcylation and PI3K/AKT/mTOR Axis in Human Chronic Diseases
P2860
Q26744659-A731ED47-0CE3-4872-80EE-D5E6CA4D80D0Q30843650-5D55B901-E87F-4092-9A38-5B4211C85308Q33706940-90F05A00-8B29-4B47-852B-F74E6F8417BBQ36523637-A2E6FB29-8599-447B-823C-AEF62227BC6BQ36654176-9C1BCBC0-DB08-4F46-8A89-A778129B68E3Q37137415-1AAFBAEE-859C-41C3-A497-2303D6B1BC2DQ37549786-E55C4691-B0C5-4DC8-B43B-3A47E65077A9Q38719469-82D9D152-C111-4A61-9732-5860353F4894Q38761409-09EFE0B7-B7A6-4510-8918-09DEB99EC9F4Q38920683-58E96E66-BDA9-4C33-9366-6FB958E03B00Q39295247-100E3847-2BED-47F3-8E4E-E27D449E9D41Q39324009-D5476938-56B0-4ADF-8FEE-EB7BCA54EBE7Q39406240-8DAF5906-87DA-45A8-B4E6-A05023EBB47DQ41064100-4A0909B2-AAF5-485B-9BDA-F1B06CB0D656Q45937542-F19C30BE-4515-4E6C-BBF9-BF3EC3A48ED4Q45948370-653235EE-C37A-44D5-B6F8-722D0809A6F4Q45985041-C6777E3E-9947-4D1A-AE0E-70AF6570D9EFQ47628534-14E8A4BD-79FB-49A2-AD5B-B693AED680EEQ47810690-B51288D8-C53A-4A92-876E-C4D5F4E685A1Q48168963-D815F12C-3057-4A8D-A363-C0F03C2BE7A8Q48330331-8F94DEEC-F3AF-4A3A-8110-7A76CCDEEAEAQ49874500-03021C48-6D53-4398-97A1-7842E6004CC9Q49913262-7C405D54-8A2F-4BF5-AE85-692BBEF8BF12Q50880151-B0BA4CC3-5849-45C9-97F0-0E6BD1602087Q52714245-1CA5F655-B430-4305-AD9B-8629CC87637CQ53376530-1E81E1A6-598F-4EDE-A4FC-E5AA351B347FQ55226753-710ACDAA-46EE-4AE0-B1C2-73C4DAFD2D37Q55416370-666A7A54-2989-42F7-96F8-AEEBB1CC45B4Q57816633-46FCE99B-30F2-47E4-9417-CFDCB3A6FDC9
P2860
O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson's disease
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
O-GlcNAc modification blocks t ...... iated with Parkinson's disease
@ast
O-GlcNAc modification blocks t ...... iated with Parkinson's disease
@en
type
label
O-GlcNAc modification blocks t ...... iated with Parkinson's disease
@ast
O-GlcNAc modification blocks t ...... iated with Parkinson's disease
@en
prefLabel
O-GlcNAc modification blocks t ...... iated with Parkinson's disease
@ast
O-GlcNAc modification blocks t ...... iated with Parkinson's disease
@en
P2093
P2860
P356
P1433
P1476
O-GlcNAc modification blocks t ...... iated with Parkinson's disease
@en
P2093
Don B Arnold
Mark R Ambroso
Matthew R Pratt
Maxwell T Roth
Nicholas P Marotta
Ralf Langen
Yu Hsuan Lin
Yuka E Lewis
P2860
P2888
P304
P356
10.1038/NCHEM.2361
P50
P577
2015-10-12T00:00:00Z